These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 9363157)

  • 21. Low-molecular weight heparin as prophylaxis against thromboembolism after total hip replacement--is it worth the price?
    Persson BM
    Acta Orthop Scand; 2000 Apr; 71(2):215-6. PubMed ID: 10852334
    [No Abstract]   [Full Text] [Related]  

  • 22. Advances in the prevention of venous thromboembolic disease in orthopaedics: the introduction of LMWH.
    Colwell CW; Paiement G; Pellegrini VD; Salvati EA; Stulberg BN
    Contemp Orthop; 1993 Dec; 27(6):551-77. PubMed ID: 10146586
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
    Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
    Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin?
    Jaff MR
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S17-21. PubMed ID: 19213061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
    Schousboe JT; Brown GA
    J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prophylaxis of postoperative thromboembolism. New alternatives to low-molecular-weight heparin].
    Bergqvist D; Siegbahn A
    Lakartidningen; 2002 Jul; 99(28-29):3039-41. PubMed ID: 12170516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in the use of oral anticoagulants.
    Lassen MR
    Expert Opin Pharmacother; 2009 Aug; 10(11):1769-81. PubMed ID: 19548861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme.
    Hull RD; Pineo GF
    Int Angiol; 1998 Sep; 17(3):131-4. PubMed ID: 9821024
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
    Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
    Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular-weight heparin: from the bench to the orthopedic patient.
    Turpie AG
    Orthopedics; 1997 Feb; 20 Suppl():10-3. PubMed ID: 9048401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and potential uses of low molecular weight heparin: a review and an economic analysis.
    Seo P; Locke CF
    Am J Manag Care; 2000 Apr; 6(4):498-506; quiz 507-8. PubMed ID: 10977456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of standard unfractionated and low-molecular-weight heparins on platelets of patients undergoing total hip replacement surgery.
    Aulmann M; Kwasniki S; Böttiger BW; Meeder PJ
    Beitr Infusionsther Transfusionsmed; 1997; 34():242-7. PubMed ID: 9356680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Low-molecular-weight heparin for preventing deep-vein thrombosis after total joint arthroplasty].
    Yang G; Lu H; Gao J; Kou B; Yuan Y; Xu B
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):25-7. PubMed ID: 11831980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
    Friedman RJ; Sengupta N; Lees M
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):299-306. PubMed ID: 21671699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
    Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.